WO2009051220A1 - Aβオリゴマーに特異的に結合する抗体およびその利用 - Google Patents
Aβオリゴマーに特異的に結合する抗体およびその利用 Download PDFInfo
- Publication number
- WO2009051220A1 WO2009051220A1 PCT/JP2008/068848 JP2008068848W WO2009051220A1 WO 2009051220 A1 WO2009051220 A1 WO 2009051220A1 JP 2008068848 W JP2008068848 W JP 2008068848W WO 2009051220 A1 WO2009051220 A1 WO 2009051220A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- oligomer
- specifically binding
- antibody capable
- recognize
- soluble
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Pathology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2008312802A AU2008312802A1 (en) | 2007-10-19 | 2008-10-17 | Antibody capable of specifically binding to abeta oligomer, and use thereof |
CN2008801222168A CN101965365A (zh) | 2007-10-19 | 2008-10-17 | 能够特异性结合Aβ寡聚体的抗体及其应用 |
JP2009538166A JPWO2009051220A1 (ja) | 2007-10-19 | 2008-10-17 | Aβオリゴマーに特異的に結合する抗体およびその利用 |
EP08839297A EP2210901A4 (en) | 2007-10-19 | 2008-10-17 | ANTIBODY CAPABLE OF BINDING SPECIFICALLY TO OLIGOMER A, AND USE THEREOF |
CA2702880A CA2702880A1 (en) | 2007-10-19 | 2008-10-17 | Antibody capable of specifically binding to a beta oligomer, and use thereof |
US12/762,878 US20100260783A1 (en) | 2007-10-19 | 2010-04-19 | Antibody Specific Binding to A Beta Oligomer and the Use |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007272015 | 2007-10-19 | ||
JP2007-272015 | 2007-10-19 | ||
US8554008P | 2008-08-01 | 2008-08-01 | |
US61/085,540 | 2008-08-01 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/533,294 Continuation-In-Part US20100291071A1 (en) | 2007-10-19 | 2009-07-31 | Antibody Specific Binding to A-Beta Oligomer and the Use |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2009051220A1 true WO2009051220A1 (ja) | 2009-04-23 |
Family
ID=40567481
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2008/068848 WO2009051220A1 (ja) | 2007-10-19 | 2008-10-17 | Aβオリゴマーに特異的に結合する抗体およびその利用 |
Country Status (9)
Country | Link |
---|---|
US (1) | US20100260783A1 (ja) |
EP (1) | EP2210901A4 (ja) |
JP (1) | JPWO2009051220A1 (ja) |
KR (1) | KR20100115340A (ja) |
CN (1) | CN101965365A (ja) |
AU (1) | AU2008312802A1 (ja) |
CA (1) | CA2702880A1 (ja) |
SG (1) | SG185316A1 (ja) |
WO (1) | WO2009051220A1 (ja) |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010119704A1 (en) | 2009-04-17 | 2010-10-21 | Immunas Pharma, Inc. | Antibodies that specifically bind to a beta oligomers and use thereof |
WO2011016567A1 (ja) | 2009-08-07 | 2011-02-10 | 協和発酵キリン株式会社 | 抗アミロイドβオリゴマーヒト化抗体 |
WO2011016239A1 (en) | 2009-08-06 | 2011-02-10 | Immunas Pharma, Inc. | Antibodies that specifically bind to a beta oligomers and use thereof |
WO2011016568A1 (ja) | 2009-08-07 | 2011-02-10 | 協和発酵キリン株式会社 | 抗アミロイドβオリゴマーヒト化抗体 |
WO2011016238A1 (en) | 2009-08-06 | 2011-02-10 | Immunas Pharma, Inc. | Antibodies that specifically bind to a beta oligomers and use thereof |
US8378081B2 (en) | 2008-02-08 | 2013-02-19 | Immunas Pharma, Inc. | Antibodies that specifically bind to Aβ oligomers and uses thereof |
JP2015502551A (ja) * | 2011-12-23 | 2015-01-22 | フォルシュングスツェントルム ユーリッヒ ゲゼルシャフ | Aβ凝集体の選択的定量化方法 |
US9085614B2 (en) | 2008-08-01 | 2015-07-21 | Immunas Pharma, Inc. | Antibodies that specifically bind to Aβ oligomers and uses thereof |
RU2575095C2 (ru) * | 2009-08-07 | 2016-02-10 | Киова Хакко Кирин Ко., Лтд. | Гуманизированное антитело против олигомера бета-амилоида |
EP3204414A4 (en) * | 2014-10-07 | 2018-03-21 | Ann and Robert H. Lurie Children's Hospital of Chicago | Novel anti-nodal antibodies and methods of using same |
US11434283B2 (en) | 2020-07-23 | 2022-09-06 | Othair Prothena Limited | Anti-abeta antibodies |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL199534A (en) | 2007-01-05 | 2013-01-31 | Univ Zuerich | An isolated human antibody capable of detecting a neoepitope in a disease-related protein, a polynucleotide encoding an antibody, a vector containing the polynucleotide, a host cell containing the polynucleotide or vector, a preparation containing the antibody and related methods and uses. |
KR20120017469A (ko) | 2007-01-05 | 2012-02-28 | 유니버시티 오브 취리히 | 질환 특이적 결합 분자 및 표적을 제공하는 방법 |
US20100291071A1 (en) * | 2008-08-01 | 2010-11-18 | Immunas Pharma, Inc. | Antibody Specific Binding to A-Beta Oligomer and the Use |
MX2011006422A (es) | 2008-12-19 | 2011-09-15 | Panima Pharmaceuticals Ag | Autoanticuerpos humanos anti-alfa-sinucleina. |
UA107571C2 (xx) | 2009-04-03 | 2015-01-26 | Фармацевтична композиція | |
AU2013205313B2 (en) * | 2010-10-07 | 2016-05-19 | Ac Immune S.A. | Phosphospecific antibodies recognising tau |
EP2625198B1 (en) * | 2010-10-07 | 2015-07-22 | AC Immune S.A. | Antibodies recognising phospho-tau |
SI2723379T1 (sl) | 2011-06-23 | 2019-03-29 | Biogen International Neuroscience Gmbh | Molekule, ki se vežejo ma anti alfa-sinuklein |
CN108034005B (zh) | 2011-10-07 | 2021-06-25 | Ac免疫有限公司 | 识别Tau的磷酸化特异抗体 |
JP6293731B2 (ja) | 2012-04-05 | 2018-03-14 | エーシー イミューン エス.エー. | ヒト化タウ抗体 |
WO2013167681A1 (en) | 2012-05-10 | 2013-11-14 | Georg-August-Universität Göttingen | CONFORMATIONAL-SPECIFIC ANTIBODIES AGAINST Αβ OLIGOMERS |
WO2014150877A2 (en) | 2013-03-15 | 2014-09-25 | Ac Immune S.A. | Anti-tau antibodies and methods of use |
CN105283196B (zh) * | 2013-03-15 | 2018-10-12 | 贝丝以色列女执事医疗中心 | 用于产生和使用构象-特异性抗体的方法和组合物 |
MA41115A (fr) | 2014-12-02 | 2017-10-10 | Biogen Int Neuroscience Gmbh | Procédé de traitement de la maladie d'alzheimer |
EP3341021A4 (en) | 2015-08-27 | 2019-03-13 | Celldex Therapeutics, Inc. | ANTI-ALK ANTIBODIES AND METHOD OF USE THEREOF |
TW201902927A (zh) | 2017-04-21 | 2019-01-16 | 美商梅利特公司 | 糖尿病相關應用之方法及抗體 |
MX2020001855A (es) | 2017-08-22 | 2020-08-13 | Biogen Ma Inc | Composiciones farmacéuticas que contienen anticuerpos anti-beta-amiloides. |
KR20200077543A (ko) | 2017-10-25 | 2020-06-30 | 얀센 파마슈티칼즈, 인코포레이티드 | 인산화 타우 펩티드의 조성물 및 이의 용도 |
US11629184B2 (en) | 2018-02-23 | 2023-04-18 | Remd Biotherapeutics, Inc. | Calcitonin gene-related peptide (CGRP) antagonist antibodies |
CN110818796B (zh) * | 2018-08-09 | 2022-11-08 | 东莞市朋志生物科技有限公司 | 一种抗人ca153蛋白的重组抗体 |
US20220026445A1 (en) * | 2018-12-07 | 2022-01-27 | Georgia Tech Research Corporation | Antibodies that bind to natively folded myocilin |
WO2020163730A2 (en) | 2019-02-08 | 2020-08-13 | Ac Immune S.A. | Method of safe administration of phosphorylated tau peptide vaccine |
EP3965817A4 (en) | 2019-04-24 | 2023-11-22 | Janssen Pharmaceuticals, Inc. | HETEROLOGUE ADMINISTRATION OF TAU VACCINES |
US20230034474A1 (en) * | 2019-09-10 | 2023-02-02 | Ac Immune Sa | Novel Molecules for Diagnosis |
Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6317688A (ja) | 1986-03-28 | 1988-01-25 | Kimiyoshi Tsuji | ヒト―ヒトハイブリドーマの製造法 |
WO1990007861A1 (en) | 1988-12-28 | 1990-07-26 | Protein Design Labs, Inc. | CHIMERIC IMMUNOGLOBULINS SPECIFIC FOR p55 TAC PROTEIN OF THE IL-2 RECEPTOR |
WO1992003918A1 (en) | 1990-08-29 | 1992-03-19 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
WO1994002602A1 (en) | 1992-07-24 | 1994-02-03 | Cell Genesys, Inc. | Generation of xenogeneic antibodies |
WO1994025585A1 (en) | 1993-04-26 | 1994-11-10 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
WO1996034096A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
WO1996033735A1 (en) | 1995-04-27 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
WO2003104437A2 (en) * | 2002-06-11 | 2003-12-18 | Northwestern University | Anti-addl antibodies and uses thereof |
WO2006055178A2 (en) * | 2004-10-25 | 2006-05-26 | Merck & Co., Inc. | Anti-addl antibodies and uses thereof |
WO2006094724A2 (en) * | 2005-03-05 | 2006-09-14 | Abbott Gmbh & Co. Kg | Screening method, process for purifying of non-diffusible a-beta oligomers, selective antibodies against said non-diffusible a-beta oligomers and a process for manufacturing of said antibodies |
WO2006137354A1 (ja) * | 2005-06-21 | 2006-12-28 | Medical & Biological Laboratories Co., Ltd. | アミロイド線維形成に対する阻害活性を有する抗体 |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6218506B1 (en) * | 1997-02-05 | 2001-04-17 | Northwestern University | Amyloid β protein (globular assembly and uses thereof) |
AR022952A1 (es) * | 1999-03-19 | 2002-09-04 | Smithkline Beecham Corp | ANTICUERPO MONOCLONAL DE ROEDOR ESPECIFICAMENTE NEUTRALIZANTE PARA LA INTERLEUQUINA-18 HUMANA , UN FRAGMENTO FAB NEUTRALIZANTE o FRAGMENTO F(AB')2, UNA REGION DE COMPLEMENTARIEDAD DE CADENA LIGERA DE INMONOGLOBULINA(CDR), UNA MOLECULA DE ACIDO NUCLEICO, COMPOSICION FARMACEUTICA QUE LO COMPRENDE, EL |
EP1420032B2 (en) * | 2001-08-03 | 2015-12-16 | Medical & Biological Laboratories Co., Ltd. | Antibody recognizing gm1 ganglioside-bound amyloid beta-protein and dna encoding the antibody |
DE10303974A1 (de) * | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
US8394379B2 (en) * | 2003-05-15 | 2013-03-12 | Iogenetics, Llc | Targeted cryptosporidium biocides |
CA2572602A1 (en) * | 2004-07-02 | 2006-02-09 | Northwestern University | Monolocal antibodies that target pathological assemblies of amyloid .beta. (abeta) |
WO2006047254A1 (en) * | 2004-10-22 | 2006-05-04 | Regents Of The University Of Minnesota | Assemblies of oligomeric amyloid beta protein and uses thereof |
CA2790433A1 (en) * | 2004-10-25 | 2006-05-26 | Northwestern University | Anti-addl antibodies and uses thereof |
EP1838349A1 (en) * | 2004-12-15 | 2007-10-03 | Neuralab, Ltd. | Amyloid beta antibodies for use in improving cognition |
US7731962B2 (en) * | 2005-02-14 | 2010-06-08 | Merck & Co., Inc. | Anti-ADDL monoclonal antibody and use thereof |
EP1749839A1 (en) * | 2005-07-22 | 2007-02-07 | Novoplant GmbH | Antigen binding polypeptides against F4(K88) fimbriae |
CN1329413C (zh) * | 2006-01-23 | 2007-08-01 | 南京医科大学 | 一种治疗或预防老年性痴呆的抗体及其表达载体和在制药中的应用 |
US20100291071A1 (en) * | 2008-08-01 | 2010-11-18 | Immunas Pharma, Inc. | Antibody Specific Binding to A-Beta Oligomer and the Use |
PL2246427T3 (pl) * | 2008-02-08 | 2017-06-30 | Immunas Pharma, Inc. | Przeciwciała zdolne do wiązania się swoiście do oligomerów amyloidu beta i ich stosowanie |
US9085614B2 (en) * | 2008-08-01 | 2015-07-21 | Immunas Pharma, Inc. | Antibodies that specifically bind to Aβ oligomers and uses thereof |
EP2419447B1 (en) * | 2009-04-17 | 2017-08-23 | Immunas Pharma, Inc. | Antibodies that specifically bind to a beta oligomers and use thereof |
ES2614949T3 (es) * | 2009-08-06 | 2017-06-02 | Immunas Pharma, Inc. | Anticuerpos que se unen específicamente a oligómeros beta A y uso de los mismos |
ES2624835T3 (es) * | 2009-08-06 | 2017-07-17 | Immunas Pharma, Inc. | Anticuerpos que se unen específicamente a los oligómeros A beta y uso de los mismos |
-
2008
- 2008-10-17 AU AU2008312802A patent/AU2008312802A1/en not_active Abandoned
- 2008-10-17 CN CN2008801222168A patent/CN101965365A/zh active Pending
- 2008-10-17 KR KR1020107010773A patent/KR20100115340A/ko not_active Application Discontinuation
- 2008-10-17 JP JP2009538166A patent/JPWO2009051220A1/ja active Pending
- 2008-10-17 CA CA2702880A patent/CA2702880A1/en not_active Abandoned
- 2008-10-17 SG SG2012077319A patent/SG185316A1/en unknown
- 2008-10-17 EP EP08839297A patent/EP2210901A4/en not_active Withdrawn
- 2008-10-17 WO PCT/JP2008/068848 patent/WO2009051220A1/ja active Application Filing
-
2010
- 2010-04-19 US US12/762,878 patent/US20100260783A1/en not_active Abandoned
Patent Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6317688A (ja) | 1986-03-28 | 1988-01-25 | Kimiyoshi Tsuji | ヒト―ヒトハイブリドーマの製造法 |
WO1990007861A1 (en) | 1988-12-28 | 1990-07-26 | Protein Design Labs, Inc. | CHIMERIC IMMUNOGLOBULINS SPECIFIC FOR p55 TAC PROTEIN OF THE IL-2 RECEPTOR |
WO1992003918A1 (en) | 1990-08-29 | 1992-03-19 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
WO1994002602A1 (en) | 1992-07-24 | 1994-02-03 | Cell Genesys, Inc. | Generation of xenogeneic antibodies |
WO1994025585A1 (en) | 1993-04-26 | 1994-11-10 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
WO1996033735A1 (en) | 1995-04-27 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
WO1996034096A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
WO2003104437A2 (en) * | 2002-06-11 | 2003-12-18 | Northwestern University | Anti-addl antibodies and uses thereof |
WO2006055178A2 (en) * | 2004-10-25 | 2006-05-26 | Merck & Co., Inc. | Anti-addl antibodies and uses thereof |
WO2006094724A2 (en) * | 2005-03-05 | 2006-09-14 | Abbott Gmbh & Co. Kg | Screening method, process for purifying of non-diffusible a-beta oligomers, selective antibodies against said non-diffusible a-beta oligomers and a process for manufacturing of said antibodies |
WO2006137354A1 (ja) * | 2005-06-21 | 2006-12-28 | Medical & Biological Laboratories Co., Ltd. | アミロイド線維形成に対する阻害活性を有する抗体 |
Non-Patent Citations (58)
Title |
---|
BARD F, NAT MED |
CABILLY ET AL., PROC. NATL. ACAD. SCI. USA, vol. 81, 1984, pages 3273 - 7 |
DEANE R, J NEUROSCI, 2005 |
DEMATTOS RB ET AL., PNAS, vol. 98, 2001, pages 8850 - 8855 |
DEMATTOS RB, PNAS, 2001 |
ETSURO MATSUBARA: "Alzheimer-byo Hassho Byotai Kiban o nasu Shinkei Dokusei Ap Oligomer", DAI 49 KAI THE JAPANESE SOCIETY FOR NEUROCHEMISTRY SOKAI PROGRAM · SHOROKUSHU, 2008, pages 84, XP008134944 * |
GHISO J ET AL., BIOCHEM J, 1993 |
HASHIMOTO-GOTOH, T. ET AL., GENE, vol. 152, 1995, pages 271 - 275 |
HASS C ET AL., NATURE REVIEW, vol. 8, 2007, pages 101 - 12 |
HOPP, T.P. ET AL., BIOTECHNOLOGY, vol. 6, 1988, pages 1204 - 1210 |
ISHIDA I ET AL., CLONING AND STEM CELLS, vol. 4, 2002, pages 91 - 102 |
JANUS D, NATURE, 2000 |
JONES ET AL., NATURE, vol. 321, 1986, pages 522 - 5 |
KATSUNO ET AL., NEUROLOGY, vol. 64, 2005, pages 687 - 692 |
KATSUNO T, NEUROLOGY, vol. 64, 2005, pages 687 - 692 |
KAYED R ET AL., SCIENCE, vol. 300, 2003, pages 486 - 489 |
KAYED R. ET AL.: "Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis.", SCIENCE, vol. 300, 2003, pages 486 - 489, XP002379307 * |
KAYED R. ET AL.: "Fibril specific, conformation dependent antibodies recognize a generic epitope common to amyloid fibrils and fibrillar oligomers that is absent in prefibrillar oligomers.", MOLECULAR NEURODEGENERATION, vol. 2, no. 18, September 2007 (2007-09-01), XP021039868 * |
KLEIN WL, TRENDS NEUROSCI, 2001 |
KLEIN WL, TRENDS NEUROSCI., vol. 24, 2001, pages 219 - 224 |
KOHLER G.; MILSTEIN C., METHODS ENZYMOL., vol. 73, 1981, pages 3 - 46 |
KOHLER; MILSTEIN, NATURE, vol. 256, 1975, pages 495 - 7 |
KRAMER W; FRITZ HJ, METHODS. ENZYMOL., vol. 154, 1987, pages 350 - 367 |
KRAMER, W. ET AL., NUCLEIC ACIDS RES., vol. 12, 1984, pages 9441 - 9456 |
KUNKEL, METHODS ENZYMOL., vol. 85, 1988, pages 2763 - 2766 |
KUNKEL, TA, PROC. NATL. ACAD. SCI. USA., vol. 82, 1985, pages 488 - 492 |
LAMBERT M. ET AL.: "Vaccination with soluble Ap oligomers generates toxicity-neutralizing antibodies.", JOURNAL OF NEUROCHEMISTRY, vol. 79, 2001, pages 595 - 605, XP008134707 * |
LARRICK ET AL., METHODS: A COMPANION TO METHODS IN ENZYMOLOGY, vol. 2, 1991, pages 106 |
LEE B. ET AL.: "Targeting amyloid-P peptide (AP) oligomers by passive immunization with a conformation-selective monoclonal antibody improves learning and memory in Ap precursor protein (APP) transgenic mice.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 281, no. 7, 2006, pages 4292 - 4299, XP003013340 * |
LEE EB ET AL., J BIOL CHEM, vol. 281, 2006, pages 4292 - 4299 |
LEE EB ET AL., J. BIOL. CHEM., vol. 281, 2006, pages 4292 - 4299 |
LESNE S. ET AL.: "A specific amyloid-? protein assembly in the brain impairs memory.", NATURE, vol. 440, 2006, pages 352 - 357, XP002408133 * |
MATSUBARA E ET AL., ANN NEUROL, 1999, pages 537 - 541 |
MATSUBARA E ET AL., ANN NEUROL, vol. 45, 1999, pages 537 - 541 |
MATSUBARA E ET AL., NEUROBIOL AGING, 2004 |
MATSUBARA E ET AL., NEUROBIOL AGING, vol. 25, 2004, pages 833 - 841 |
MATSUBARA E. ET AL., NEUROBIOL AGING, vol. 25, 2004, pages 833 - 841 |
MATSUBARA E. ET AL.: "Abeta Oligomer Kotai ni yoru Alzheimer-byo Shindan System no Kaihatsu", DAI 46 KAI PROGRAM AND ABSTRACTS OF THE MEETING OF THE JAPANESE SOCIETY OF NEUROLOGY, 2005, pages 95, XP008134943 * |
MATSUBARA E.: "Abeta Oligomer", DEMENTIA JAPAN, vol. 21, no. 3, December 2007 (2007-12-01), pages 253 - 260, XP008141246 * |
MATSUBARA E.: "Alzheimer-byo ni Okeru Ap Oligomer Tokuiteki Judo Men'eki Ryoho", ABSTRACTS OF 128TH ANNUAL MEETING OF PHARMACEUTICAL SOCIETY OF JAPAN, 2008, pages 222, S38 - 4, XP008134945 * |
MICHAEL A ET AL., PROC. NATL. ACAD. SCI. USA, vol. 91, 1994, pages 969 - 73 |
MORGAN D, NATURE, 2000 |
MOURI A, FASEB J, vol. 21, 2007, pages 2135 - 2148 |
NAKAYA Y ET AL., J BIOL CHEM, vol. 280, 2005, pages 19070 - 19077 |
PRESTA, CURR. OPIN. STRUCT. BIOL., vol. 2, 1992, pages 593 - 6 |
QUEEN ET AL., PROC. NATL. ACAD. SCI. USA, vol. 86, 1989, pages 10029 - 33 |
RIECHMANN ET AL., NATURE, vol. 332, 1988, pages 323 - 7 |
See also references of EP2210901A4 * |
SELKOE DJ, SCIENCE, 2002 |
SELKOE DJ, SCIENCE, vol. 298, 2002, pages 789 - 791 |
SHOJI M. ET AL.: "Abeta Peptide no Byogensei Kento to Byogensei Abeta Oligomer Jokyo Ryoho Kaihatsu", KOSEI RODO KAGAKU KENKYUHI HOJOKIN (TOKUTEI SHIKKAN TAISAKU KENKYU JIGYO) AMYLOID CHINCHAKU NI YORU BYOTEKI YOSO NO TANSAKU NI KANSURU KENKYU BUNTAN KENKYU HOKOKUSHO, 2004, pages 68 - 72, XP008134942 * |
SHOJI M. ET AL.: "Alzheimer-byo no Kotai Chiryo", KOSEI RODO KAGAKU KENKYUHI HOJOKIN (NANCHISEI SHIKKAN KOKUFUKU KENKYU JIGYO) AMYLOIDOSIS NI KANSURU CHOSA KENKYUHAN BUNTAN KENKYU HOKOKUSHO, 2008, pages 76 - 78, XP008134941 * |
SUN H. ET AL.: "Characterization of therapeutic antibody against Abeta", OLIGOMERS FOR ALZHEIMERS DISEASE., vol. 21, no. 2, 15 August 2007 (2007-08-15), pages 2 - 261, XP008141247 * |
TERO, R ET AL., LANGMUIR, vol. 20, 2004, pages 7526 - 7531 |
VERHOEYEN ET AL., SCIENCE, vol. 239, 1988, pages 1534 - 6 |
WRZOLEK MA ET AL., AM J PATHOL, vol. 141, 1992, pages 343 - 355 |
YAMAMOTO N ET AL., J BIOL CHEM, vol. 282, 2007, pages 2646 - 2655 |
ZOLLER, MJ; SMITH, M., METHODS ENZYMOL., vol. 100, 1983, pages 468 - 500 |
Cited By (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9090680B2 (en) | 2008-02-08 | 2015-07-28 | Immunas Pharma, Inc. | Antibodies that specifically bind to abeta oligomers and uses thereof |
US8378081B2 (en) | 2008-02-08 | 2013-02-19 | Immunas Pharma, Inc. | Antibodies that specifically bind to Aβ oligomers and uses thereof |
US9085614B2 (en) | 2008-08-01 | 2015-07-21 | Immunas Pharma, Inc. | Antibodies that specifically bind to Aβ oligomers and uses thereof |
US9090679B2 (en) | 2009-04-17 | 2015-07-28 | Immunas Pharma, Inc. | Antibodies that specifically bind to A beta oligomers and use thereof |
WO2010119704A1 (en) | 2009-04-17 | 2010-10-21 | Immunas Pharma, Inc. | Antibodies that specifically bind to a beta oligomers and use thereof |
US8858949B2 (en) | 2009-08-06 | 2014-10-14 | Immunas Pharma, Inc. | Antibodies that specifically bind to a beta oligomers and use thereof |
EP2462161A1 (en) * | 2009-08-06 | 2012-06-13 | Immunas Pharma, Inc. | Antibodies that specifically bind to a beta oligomers and use thereof |
EP2462162A1 (en) * | 2009-08-06 | 2012-06-13 | Immunas Pharma, Inc. | Antibodies that specifically bind to a beta oligomers and use thereof |
WO2011016238A1 (en) | 2009-08-06 | 2011-02-10 | Immunas Pharma, Inc. | Antibodies that specifically bind to a beta oligomers and use thereof |
CN102574915A (zh) * | 2009-08-06 | 2012-07-11 | 伊缪纳斯制药株式会社 | 特异性结合Aβ寡聚体的抗体及其用途 |
US8613924B2 (en) | 2009-08-06 | 2013-12-24 | Immunas Pharma, Inc. | Antibodies that specifically bind to A beta oligomers and use thereof |
JP2013500940A (ja) * | 2009-08-06 | 2013-01-10 | イムナス・ファーマ株式会社 | Aβオリゴマーに特異的に結合する抗体およびその利用 |
JP2013500941A (ja) * | 2009-08-06 | 2013-01-10 | イムナス・ファーマ株式会社 | Aβオリゴマーに特異的に結合する抗体およびその利用 |
WO2011016239A1 (en) | 2009-08-06 | 2011-02-10 | Immunas Pharma, Inc. | Antibodies that specifically bind to a beta oligomers and use thereof |
EP2462162A4 (en) * | 2009-08-06 | 2013-05-22 | Immunas Pharma Inc | SPECIFIC TO ABETA OLIGMOMER BINDING ANTIBODIES AND THEIR USE |
EP2462161A4 (en) * | 2009-08-06 | 2013-05-29 | Immunas Pharma Inc | SPECIFIC TO ABETA OLIGMOMER BINDING ANTIBODIES AND THEIR USE |
EP2463368A4 (en) * | 2009-08-07 | 2013-09-18 | Kyowa Hakko Kirin Co Ltd | OLIGOMERIC HUMANIZED ANTI-SUBSTANCE B-AMYLOID ANTIBODY |
RU2575095C2 (ru) * | 2009-08-07 | 2016-02-10 | Киова Хакко Кирин Ко., Лтд. | Гуманизированное антитело против олигомера бета-амилоида |
US8303954B2 (en) | 2009-08-07 | 2012-11-06 | Kyowa Hakko Kirin Co., Ltd | Anti-Aβ oligomer humanized antibody |
EP2463368A1 (en) * | 2009-08-07 | 2012-06-13 | Kyowa Hakko Kirin Co., Ltd. | Humanized anti-amyloid-b oligomer antibody |
KR101787118B1 (ko) | 2009-08-07 | 2017-10-18 | 교와 핫꼬 기린 가부시키가이샤 | 항아밀로이드β 올리고머 인간화 항체 |
EP2463369A1 (en) * | 2009-08-07 | 2012-06-13 | Kyowa Hakko Kirin Co., Ltd. | Humanized anti-amyloid-b oligomer antibody |
WO2011016568A1 (ja) | 2009-08-07 | 2011-02-10 | 協和発酵キリン株式会社 | 抗アミロイドβオリゴマーヒト化抗体 |
WO2011016567A1 (ja) | 2009-08-07 | 2011-02-10 | 協和発酵キリン株式会社 | 抗アミロイドβオリゴマーヒト化抗体 |
US9181332B2 (en) | 2009-08-07 | 2015-11-10 | Kyowa Hakko Kirin Co., Ltd | Anti-A(β) oligomer humanized antibody |
EP2463369A4 (en) * | 2009-08-07 | 2013-09-18 | Kyowa Hakko Kirin Co Ltd | HUMANIZED ANTIBODIES AGAINST AMYLOID B OLIGOMERS |
JP2015502551A (ja) * | 2011-12-23 | 2015-01-22 | フォルシュングスツェントルム ユーリッヒ ゲゼルシャフ | Aβ凝集体の選択的定量化方法 |
JP2019015738A (ja) * | 2011-12-23 | 2019-01-31 | フォルシュングスツェントルム ユーリッヒ ゲゼルシャフ | Aβ凝集体の選択的定量化方法 |
EP3204414A4 (en) * | 2014-10-07 | 2018-03-21 | Ann and Robert H. Lurie Children's Hospital of Chicago | Novel anti-nodal antibodies and methods of using same |
US10494428B2 (en) | 2014-10-07 | 2019-12-03 | Ann & Robert H. Lurie Children's Hosp. of Chicago | Anti-nodal antibodies and methods of using same |
US10508147B2 (en) | 2014-10-07 | 2019-12-17 | Ann & Robert H. Lurie Children's Hospital | Anti-nodal antibodies and methods of using same |
US11434283B2 (en) | 2020-07-23 | 2022-09-06 | Othair Prothena Limited | Anti-abeta antibodies |
US11434284B2 (en) | 2020-07-23 | 2022-09-06 | Othair Prothena Limited | Anti-Abeta antibodies |
US11434285B2 (en) | 2020-07-23 | 2022-09-06 | Othair Prothena Limited | Anti-Abeta antibodies |
US11440953B2 (en) | 2020-07-23 | 2022-09-13 | Othair Prothena Limited | Anti-abeta antibodies |
Also Published As
Publication number | Publication date |
---|---|
KR20100115340A (ko) | 2010-10-27 |
JPWO2009051220A1 (ja) | 2011-03-03 |
US20100260783A1 (en) | 2010-10-14 |
SG185316A1 (en) | 2012-11-29 |
EP2210901A4 (en) | 2012-04-25 |
CN101965365A (zh) | 2011-02-02 |
EP2210901A1 (en) | 2010-07-28 |
AU2008312802A1 (en) | 2009-04-23 |
AU2008312802A2 (en) | 2010-08-19 |
CA2702880A1 (en) | 2009-04-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2009051220A1 (ja) | Aβオリゴマーに特異的に結合する抗体およびその利用 | |
WO2008150946A8 (en) | HUMANIZED ANTIBODIES WHICH BIND TO Aβ (1-42) GLOBULOMER AND USES THEREOF | |
WO2006095029A3 (en) | Di-polymer protein conjugates and processes for their preparation | |
MX2009012950A (es) | ANTICUERPOS HUMANIZADOS CONTRA EL GLOBULOMERO Aß (20-42) Y SUS USOS. | |
WO2005103081A3 (en) | Human monoclonal antibodies against cd20 | |
WO2009042922A3 (en) | Peptide-peptidase inhibitor conjugates and methods of making and using same | |
WO2006108670A3 (en) | Use of cd25 antibodies in immunotherapy | |
WO2007075270A3 (en) | Multivalent immunoglobulin-based bioactive assemblies | |
WO2009035494A3 (en) | Methods for producing anti-glycan antibodies, vaccines and methods for treating cancer or infectious disease | |
WO2007007173A3 (en) | Human anti-madcam antibodies | |
WO2009083009A3 (en) | Monoclonal antibodies against cd32b | |
WO2007109354A3 (en) | Peptide-peptidase inhibitor conjugates and methods of using same | |
WO2006014638A3 (en) | ANTIBODIES TO CROSS-LINKED AMYLOID β OLIGOMERS | |
EP3301117A3 (en) | Specific binding proteins and uses thereof | |
WO2006127898A3 (en) | (s)-n-methylnaltrexone, process for its synthesis and its pharmaceutical use | |
WO2009061996A3 (en) | Antibodies that bind human dendritic and epithelial cell 205 (dec-205) | |
WO2009048538A3 (en) | Use of anti-amyloid beta antibody in ocular diseases | |
EP4279140A3 (en) | Human antibodies against tissue factor | |
WO2006035237A3 (en) | Methods and compositions relating to alzheimer's disease | |
WO2008073162A3 (en) | Lysine acetylation sites | |
WO2006099875A8 (en) | Antibodies against cd38 for treatment of multiple myeloma | |
EA200801930A1 (ru) | Биспецифическая молекула, связывающая tlr9 и cd32 и содержащая t-клеточный эпитоп, для лечения аллергий | |
WO2012142604A3 (en) | Targeting deregulated wnt signaling in cancer using stabilized alpha-helices of bcl-9 | |
WO2009048539A3 (en) | Use of anti-amyloid beta antibody in ocular diseases | |
WO2009048537A3 (en) | Humanized antibody |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200880122216.8 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08839297 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2702880 Country of ref document: CA Ref document number: 2009538166 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008312802 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 20107010773 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2905/CHENP/2010 Country of ref document: IN Ref document number: 2008839297 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2008312802 Country of ref document: AU Date of ref document: 20081017 Kind code of ref document: A |